StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ACRSBullishIndustry Newsnews
High materiality8/10

ACRS gets FDA Fast Track for modzatinib, accelerating LP program timeline

Aug 6, 2026, 4:39 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Fast Track designation with rolling review often leads to near-term upside as the regulatory path becomes more efficient and visibility around data timing increases. However, the ultimate price impact hinges on Phase 2b results and whether a NDA is pursued timely.

AI summary

What happened, with direct paths to the underlying reporting

ACRS announced FDA Fast Track designation for modzatinib (ATI-2138) to treat moderate-to-severe LP, including oral erosive LP, cutaneous LP, and lichen planopilaris. The program will begin a phased, multi-part Phase 2b trial in Q4 2026, with rolling review and potential Priority Review under Fast Track. This milestone could de-risk the program and support earlier data-driven valuation, though clinical outcomes remain uncertain.

  • FDA grants Fast Track for modzatinib in LP. Aclaris aims Phase 2b in LP in Q4 2026.
  • Fast Track enables rolling review and potential Priority Review. Could shorten path to potential approval.
  • Lichen planus has no approved therapies. Represents a significant unmet medical need.
  • Phase 2b initiation planned Q4 2026. Readouts may inform valuation.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event